Le Lézard
Classified in: Health, Science and technology
Subject: PLW

Gliknik Announces Issuance of U.S. Patent for Use of Recombinant IVIG Mimetics


BALTIMORE, April 3, 2018 /PRNewswire/ -- Gliknik Inc. today announced that the U.S. Patent & Trademark Office (PTO) has issued U.S. Patent 9,926,362, which claims methods of using compounds that have utility as recombinant mimetics of pooled human intravenous immunoglobulin (IVIG). The patent, which issued jointly to Gliknik Inc. and to the University of Maryland, Baltimore (UMB), encompasses the uses of trimers, tetramers, pentamers, hexamers, and many other structures containing two or more human IgG1 Fc domains and binding multiple low affinity Fc gamma receptors (Fc?Rs).

"We are pleased to have the U.S. PTO recognize the novelty of methods we describe for using a range of recombinant compounds to bind multiple low affinity Fc?Rs on effector cells," said Henrik Olsen, PhD, Gliknik Vice President of Drug Discovery. "We believe that such compounds will progress through clinical trials successfully and may expand the marketplace choices for patients with autoimmune diseases."

James L. Hughes, Chief Enterprise and Economic Development Officer and Vice President at UMB, added, "We are proud of this patent issuance and look forward to the potential for a marketed recombinant IVIG product that will increase options for patients. We congratulate Gliknik for successfully leading the prosecution of this patent application on behalf of Gliknik and UMB."

About IVIG

IVIG is the general name for a blood product pooled from tens of thousands of donors, mixed, separated, and highly purified to minimize viruses, prion disease, and other undesirable contaminants. IVIG is safe and effective when used to treat numerous autoimmune diseases and immune deficiency diseases. IVIG sales are approaching $10 billion annually. The worldwide supply of IVIG, which is commercialized as many brands by a number of companies, is exhausted each year since supply is limited by the number of blood donors. Therefore, there is a pressing need for a recombinant equivalent.

About Gliknik

Gliknik is a clinical-stage biopharmaceutical company with expertise in modulation of the immune system to fight disease. The company's programs are designed to address unmet needs in tumor immunology and autoimmune diseases. The Gliknik mission is to discover and develop truly innovative biologics for people living with cancer and immune disorders. Learn more at www.gliknik.com.

About University of Maryland, Baltimore

UMB, an institution of the University System of Maryland, is Maryland's only public health, law, and human services university. Six professional schools and a Graduate School confer the majority of health care, human services, and law professional degrees in Maryland each year.

This press release contains "forward-looking statements" concerning the development and commercialization of Gliknik products, the potential benefits and attributes of such products, and Gliknik expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. Gliknik undertakes no obligation to update any forward-looking statements for any reason.

 

SOURCE Gliknik Inc.


These press releases may also interest you

at 10:28
On March 28, 2024, Broncus Medical (02216.HK) (the "Company" or "we" ) announced annual results for FY 2023. In 2023, Broncus Medical earned product sales of US$12.41 million, an increase of 32% compared to the previous year. Of which, total revenue...

at 10:28
In a groundbreaking leap forward in the realm of nutrition and fitness technology, Portions Master announces the launch of its revolutionary app, set to transform the way individuals approach portion control and nutritional tracking....

at 10:28
White Glove, a leading advisor marketing company specializing in turnkey client acquisition and engagement services and a portfolio company of Rockbridge Growth Equity, today announced it has named Derek Janis as Chief Marketing Officer. This...

at 10:27
WHR Global (WHR), a relocation management company and leader in the global mobility and corporate relocation industry, announced the release of its Global Mobility Benchmark Report....

at 10:25
Humareso, a leading provider of innovative HR solutions, is proud to announce its strategic partnership with Sentinel Pay Analytics, a pioneer in comprehensive compensation benchmarking and pay equity analytics. This collaboration marks a significant...

at 10:21
Highlights of the Annual Results as of December 31, 2023: Revenue reached RMB2,155.6 millionGross profit amounted to RMB738.5 millionAdjusted non-IFRS net loss improved to RMB208.8 million, representing a significant turnaround from a negative...



News published on and distributed by: